How Can We Develop New Treatments For Idiopathic Pulmonary Fibrosis?
Moisés Selman (Instituto Nacional de Enfermedades Respiratorias, Mexico City, Mexico) and colleagues say that the lungs of patients with IPF are enriched with genes associated with lung development in the embryo. In healthy adults, these genes are switched off but they appear to be abnormally switched on in IPF. "Dysfunctional activation of embryological pathways regularly repressed in the adult life may explain the persistent nature of the disease," say the authors.
"Designing and implementing interventions that target these embryological pathways may be required to develop novel anti-IPF therapies and to significantly improve the outcome of IPF patients."
Citation: Selman M, Pardo A, Kaminski N (2008) Idiopathic pulmonary fibrosis: Aberrant recapitulation of developmental programs? PLoS Medicine 5(3): e62.
Link to the published article.
CONTACT:
Moisés Selman
Instituto Nacional de Enfermedades Respiratorias
Tlalpan 4502
Mexico City, DF 14080
Mexico
----------------------------
Article adapted by Start Sanatate from original press release.
----------------------------
About PLoS Medicine
PLoS Medicine is an open access, freely available international medical journal. It publishes original research that enhances our understanding of human health and disease, together with commentary and analysis of important global health issues. For more information, visit http://www.plosmedicine.org/
About the Public Library of Science
The Public Library of Science (PLoS) is a non-profit organization of scientists and physicians committed to making the world's scientific and medical literature a freely available public resource. For more information, visit http://www.plos.org/
Source: Josh Eveleth
Public Library of Science
Cum putem dezvolta noi tratamente pentru fibrozã pulmonarã idiopaticã? - How Can We Develop New Treatments For Idiopathic Pulmonary Fibrosis? - articole medicale engleza - startsanatate